CSI Market
Sign In | Register

Atossa Therapeutics Inc (ATOS) Annual Cash Flow Statement

Annual · GAAP · USD millions
Access ATOS quarterly Cash Flow →
This page allows investors to follow Atossa Therapeutics Inc's cash flow patterns across multiple reporting periods and assess consistency in cash generation.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Annual Report, GAAP in USD millions
ITEM 		(Dec 31 2025)
12 Months 		(Dec 31 2024) (Dec 31 2023) (Dec 31 2022) (Dec 31 2021)
Operating Activities
Income-34.77
Depreciation & amortization0.02
Amortization of Other Assets0.00
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Increase (Decrease) in Inventories0.00
R & D, Environmental and Other Expense0.00
Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal0.00
Share-based Compensation2.65
Income (Loss) from Equity Method Investments0.00
Fair Value Adjustment of Warrants0.00
Common Shares Issued For Services-
Loss On Reduction Of Inventory-
Loan Initiation Fee Accrued For Notes Payable-
Increase Decrease In Accrued Payroll-
Stock Issued During Period Value Issued For Services-
Non Cash Reclassification Of Furniture And Equipment To Prepaid Expenses-
Increase Decrease In Deferred Rent-
Increase Decrease In Warrant Liability-
Warrant Financing Expense-
Increase Decrease In Restricted Cash Operating Ativities-
Common Stock Issued For Exercise Of Common Stock Warrants-
Common Stock Tendered For Exercise Price Of Common Stock Warrants-
Equity Securities Without Readily Determinable Fair Value Impairment Loss Annual Amount-
Increase Decrease In Research And Development Tax Rebate Receivable-
Income taxes0.00
Losses/ -gains on Investments net0.00
Increase (Decrease) in Employee Related Liabilities-0.30
Increase (Decrease) in Accounts Payable3.61
Increase (Decrease) in Accrued Liabilities0.39
Increase (Decrease) in Security Deposits0.00
Prepaid Expense and Other Assets-0.95
Other Working Capital-0.41
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities0.00
Discontinued operations0.00
Net Cash flow from Operating Activities-29.76
Investing Activities
Capital Expenditures-0.02
Sale of Capital Items0.00
Short-term Investments Proceeds0.00
Short-term Investments Acq.0.00
Real Estate Investments0.00
Increase (Decrease) in Restricted Cash0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities-0.02
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock0.00
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net-71.19
Proceeds From Issuance Of Common Stock And Warrants-
Proceeds From Repayments Of Commercial Line Of Credit-
Proceeds From Exercise Of Warrants-
Proceeds From Issuance Of Redeemable Convertible Preferred Stock-
Proceeds From Issuance Of Stock Units-
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations71.19
Proceeds From Issuance Of Common Stock Net-
Proceeds From Issuance Of Common Stock Net Of Issuance Costs-
Proceeds From Issuance Of Common Stock And Warrants Net Of Issuance Costs-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities0.00
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-29.79
Total Cash Flow-29.79
4 historic quarters locked

Sign in to unlock the full Atossa Therapeutics Inc cash flow history.

Sign In Create Free Account

About Atossa Therapeutics Inc Annual Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-K filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001193125-26-124396

Figures are derived from filed reports and may be restated. Historical data is subject to revision.

Untitled Document